Filing Details

United States Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) BIOSTAR ANGEL STEM CELL CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) None (CUSIP Number) 419 Hindry Avenue, Suite E Inglewood, California 90301 ------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 16, 2018 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

====================================================================== CUSIP NO. None 13D Page 2 1. Name of Reporting Persons: Ra, Jeong Chan ------------------------------------------------------------------- 2. Check the appropriate box if a member of a group: (a) (b) ------------------------------------------------------------------- 3. SEC use only ------------------------------------------------------------------- 4. Sourt of Funds PF ------------------------------------------------------------------- 5. Check if disclosure of legal proceeding is required pursuant to Itmes 2(d) or 2(e) [ X ] ------------------------------------------------------------------- 6. Citizenship or place of organization: Republic of Korea ------------------------------------------------------------------- NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7. Sole Voting Power: 4,500,000 shares common directly owned 10,000,000 shares preferred directly owned. Each share of preferred is entitled to 10 votes totaling 104,500,000 voting shares ------------------------------------------------------------------- 8. Shared Voting Power: 0 ------------------------------------------------------------------- 9. Sole Dispositive Power: 4,500,000 shares of common stock 10,000,000 shares of preferred stock ------------------------------------------------------------------- 10. Shared Dispositive Power: 0 ------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 4,500,000 shares common 10,000,000 shares preferred ------------------------------------------------------------------- 12. Check if The Aggregate Amount in Row 11 Excludes Certain Shares. / / [ ] ------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row 11 42% of common stock 100% of preferred stock (based on 10,680,000 shares of common stock outstanding and 10,000,000 shares of preferred stock outstanding) ------------------------------------------------------------------- 14. Type of Reporting Person: Individual ====================================================================== CUSIP NO. None 13D Page 3 Item 1 Security and Issuer (a) Name of Issuer: Biostar Angel Stem Cell Corporation (b) Address of Issuer's 419 Hindry Avenue, Suite E Inglewood, CA 90201 (c) Common stock, $0.0001 par value per share Preferred stock $0.0001 par value, 10 votes per share. ------------------------------------------------------------------- Item 2 Identity and Background (a) Name of Person Filing: Ra, Jeong-chan (b) Address of Principal Business or, if none, Residence: 104-2004, 191, Yeongsin-Ro, Yeongdeungpo-Gu Seoul, Republic of Korea (c) Principal occupation or employment: Doctor and medical researcher (d) In 2015, Mr. Ra was found guilty in the Seoul Southern District Court, affirmed in 2017 by the Seoul High Court-Court of Appeals, of (i) mishandling certain financial transactions and violating economic and financial regulations (Korean Criminal Code Article 355 and 356), (ii) violation of customs regulations (Korean Customs Code Article 270, 269 and 241), (iii) violation of foreign currency exchange regulations (Korean Foreign Currency Exchange Code Article 28 and 18), (iv) violation of pharmaceutical regulations (Korean Pharmacist Code Article 93 and 31) and (v) violation of stock trading regulations (Korean Stock Trade Code Article 188). Mr. Ra was sentenced to three years--suspended for four years-- and fined approximately USD$460,000. Mr. Ra strongly disagrees with the findings of the court and has appealed the matter to the Supreme Court of Korea which has accepted to hear the case, and when the Supreme Court of Korea renders its judgment, such judgment will then become the final judgment on these matters. (e) During the last five years, Mr. Ra has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship: Republic of Korea ------------------------------------------------------------------- Item 3. Source and Amount of Funds or Other Consideration Private funds ------------------------------------------------------------------- Item 4. Purpose of transaction Change in control of company ------------------------------------------------------------------- Item 5. Interest in Securities of Issuer (a) As of the filing date of the Schedule 13D, Mr. Ra (i) is the beneficial owner and (ii) has sole power to vote (iii) 4,500,000 shares of common stock which represents approximately 42% of the shares of common stock deemed to be outstanding pursuant to Rule 13d-1(j) and 10,000,000 shares of Preferred Stock whih represents 100% of the shares of Preferred Stock outstanding. Each shares of Preferred Stock is entitled to 10 votes giving Mr. Ra an aggregate of 104,500,000 votes of the 110,680,000 (94.%) votes outstanding. (b) The responses to Items 7-11 of the cover page of this Schedule 13D are incorporated herein. (c) Except as set forth or incorporated herein, no other transaction in the common stock has been effected during the past 60 days. (d) Not applicable. (e) Not applicable. ------------------------------------------------------------------- Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Not applicable. ------------------------------------------------------------------- Item 7. Materials to Be Filed as Exhibits Not applicable. ------------------------------------------------------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 6, 2018 /s/ Ra, Jeong-Chan -------------------------------------- Ra, Jeong-Chan